#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14636	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2072	701.8	0	.	n	.	0	A69G	SNP	69	69	A	307	307	G	842	G,A	782,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14636	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2072	701.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1688	1688	T	782	T,C	725,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14636	16S	1529	1529	99.87	16S.l15.c30.ctg.1	2072	701.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1422	1422	C	883	C	818	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27468	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3548	771.6	0	.	n	.	0	T695C	SNP	695	695	T	1088	1088	C	841	C,T	790,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27468	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3548	771.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2364	2364	C	865	C,T,A	811,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27468	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3548	771.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2438	2438	A	842	A	805	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27468	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3548	771.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2990	2990	C	838	C	786	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2028	folP	855	855	100.0	folP.l15.c4.ctg.1	1435	140.5	1	SNP	p	R229S	1	.	.	685	687	AGC	941	943	AGC	188;189;190	A;G;C,T	181;180;180,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5398	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3383	159.1	1	SNP	p	S91F	1	.	.	271	273	TTC	552	554	TTC	184;185;187	T;T;C	175;177;177	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5398	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3383	159.1	1	SNP	p	D95G	1	.	.	283	285	GGC	564	566	GGC	189;188;189	G;G;C,A,T	177;171;173,1,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5398	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3383	159.1	1	SNP	p	G95N	0	.	.	283	285	GGC	564	566	GGC	189;188;189	G;G;C,A,T	177;171;173,1,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1658	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	1389	118.8	0	.	p	.	0	D79N	NONSYN	235	237	GAT	622	624	AAT	167;167;166	A,G;A;T	156,2;156;154	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1658	mtrR	633	633	99.84	mtrR.l6.c30.ctg.1	1389	118.8	1	SNP	p	G45D	0	.	.	133	135	GGC	520	522	GGC	178;181;181	G;G,A;C	170;169,1;171	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	862	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	907	94.3	0	.	n	.	0	A197.	DEL	197	197	A	510	510	A	233	A	221	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	0	.	p	.	0	E91G	NONSYN	271	273	GAG	598	600	GGG	191;190;190	G,T;G;G	177,1;177;178	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	1	SNP	p	D86N	0	.	.	256	258	GAC	583	585	GAC	189;187;185	G;A;C,A	176;174;174,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	1	SNP	p	S87R	0	.	.	259	261	AGT	586	588	AGT	187;185;186	A;G;T	175;174;167	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	1	SNP	p	S87I	0	.	.	259	261	AGT	586	588	AGT	187;185;186	A;G;T	175;174;167	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	1	SNP	p	S87W	0	.	.	259	261	AGT	586	588	AGT	187;185;186	A;G;T	175;174;167	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4800	parC	2304	2304	99.87	parC.l15.c30.ctg.1	2917	164.1	1	SNP	p	S88P	0	.	.	262	264	TCC	589	591	TCC	188;190;192	T;C;C	174;178;179	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4156	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2686	154.2	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1636	1638	CAC	208;208;206	C;A;C	193;193;191	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4156	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2686	154.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1585	1587	GGC	198;199;200	G;G;C	184;186;187	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1233	1235	GCA	204;205;205	G;C;A	185;190;191	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1236	1238	ATC	209;209;211	A;T;C	187;189;191	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1248	1250	GTG	200;199;199	G;T;G	186;182;184	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1248	1250	GTG	200;199;199	G;T;G	186;182;184	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1752	1754	ACC	195;195;194	A;C;C	180;183;183	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1806	1808	ACG	190;193;194	A,G;C;G	155,1;160;158	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1806	1808	ACG	190;193;194	A,G;C;G	155,1;160;158	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1929	1931	GGC	197;192;191	G;G;C	174;169;170	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1938	1940	GGC	188;187;184	G;G;C	166;165;163	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4044	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2546	158.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1956	1958	CTG	173;175;177	C,G;TG,TGG;GCCC,GCCCC	131,4;136,2;133,1	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5724	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3004	189.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1633	1635	CCG	207;208;205	C;C;G	182;189;180	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2114	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1853	113.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	617	617	C	147	C	134	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2930	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1613	180.9	0	.	p	.	0	G210E	NONSYN	628	630	GGA	910	912	GAA	254;252;252	G;A;A	239;241;239	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2930	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1613	180.9	1	SNP	p	G120K	1	.	.	358	360	AAG	640	642	AAG	237;236;239	A;A;G,T	222;220;223,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2930	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1613	180.9	1	SNP	p	A121N	1	.	.	361	363	AAC	643	645	AAC	241;241;239	A,G;A;C	226,1;227;225	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2930	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1613	180.9	1	SNP	p	N121D	0	.	.	361	363	AAC	643	645	AAC	241;241;239	A,G;A;C	226,1;227;225	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11250	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4857	231.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2025	2027	CAT	266;265;265	C;A;T	246;250;248	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1186	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1072	110.2	1	SNP	p	V57M	1	.	.	169	171	ATG	516	518	ATG	259;257;255	A;T;G	240;240;237	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
